Phase 3 Trial of ROTAVAC 5D Vaccine in Chilean Infants Underway
The ongoing phase 3 trial of ROTAVAC 5D could significantly alter the competitive landscape for rotavirus vaccines. If successful, it may establish Bharat Biotech and the University of Chile as formidable players, prompting strategic shifts among existing manufacturers.
| Drug | MOA / Company | Stage |
|---|---|---|
| Phase | Bharat Biotech | Lead |
| existing rotavirus vaccine manufacturers | — | Competing |
Focal Asset
Phase
Company
Bharat Biotech
Indication
Infectious Disease / Vaccine
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The ongoing phase 3 trial of ROTAVAC 5D could significantly alter the competitive landscape for rotavirus vaccines. If successful, it may establish Bharat Biotech and the University of Chile as formidable players, prompting strategic shifts among existing manufacturers.
Why it matters
The ongoing phase 3 trial of ROTAVAC 5D could significantly alter the competitive landscape for rotavirus vaccines. If successful, it may establish Bharat Biotech and the University of Chile as formidable players, prompting strategic shifts among existing manufacturers.
What changed
Trial Update
Analysis
A phase 3 trial is evaluating the efficacy and safety of ROTAVAC 5D, a live attenuated rotavirus vaccine, in 5800 healthy infants.
The ongoing phase 3 trial of ROTAVAC 5D could significantly alter the competitive landscape for rotavirus vaccines. If successful, it may establish Bharat Biotech and the University of Chile as formidable players, prompting strategic shifts among existing manufacturers.
Monitor trial results for efficacy and safety data, as well as any regulatory submissions following the trial's completion.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.